Theratechnologies

Privately held: no public share price

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Donidalorsen(Dawnzera)
Approved
Prekallikrein (PKK) mRNARNA / oligonucleotide
Hereditary Angioedema
Ibalizumab(Trogarzo)
Approved
CD4 receptorMonoclonal antibody
HIV
Olezarsen(Tryngolza)
Approved
APOC3RNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Tesamorelin(Egrifta WR)
Approved
Growth hormone-releasing hormone (GHRH) receptorPeptide
HIV

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Donidalorsen · DawnzeraPhase 3Hereditary Angioedema
Est. primary completion 2026-12 · NCT05392114 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Olezarsen · TryngolzaPhase 3Severe Hypertriglyceridemia
Est. primary completion 2027-03 · NCT05681351 · CT.gov ↗
What to watch
June 2027 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2027-06 · NCT05185843 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Donidalorsen · DawnzeraPhase 3Hereditary Angioedema (HAE)
Est. primary completion 2029-06 · NCT07298447 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalOlezarsenEuropean Commission approves Tryngolza in severe hypertriglyceridaemia
EU, European Commission · Source ↗
19 May 2025Topline resultOlezarsenPhase 3 Essence (NCT05610280) of olezarsen met its primary endpoint
Ionis Pharmaceuticals · Source ↗
8 April 2025ApprovalTesamorelinFDA approves Prior Approval Supplement for EGRIFTA SV sBLA
US, FDA · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$86M—$16M$8.3Mreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$82M—$34M$24Mreport ↗
2022-FY$80M—$24M$47Mreport ↗
2021-FY$70M—$20M$32Mreport ↗